Savara Inc
SVRADrugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Aug 12, 2026
7dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
SVRA Earnings Report
EPS Est: $-0.14 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How SVRA's past catalysts played out
Vancomycin inhalation powder
MRSA
Molgramostim
Autoimmune Pulmonary Alveolar Proteinosis
Inhaled molgramostim
Mycobacterium Infections, Nontuberculous
Vancomycin hydrochloride inhalation powder
Cystic Fibrosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Vancomycin inhalation powder | Phase 3 | MRSA | - | - |
Molgramostim | Phase 3 | Autoimmune Pulmonary Alveolar Proteinosis | - | - |
Inhaled molgramostim | Phase 2 | Mycobacterium Infections, Nontuberculous | - | - |
Vancomycin hydrochloride inhalation powder | Phase 2 | Cystic Fibrosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Savara Inc's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Savara Inc's (SVRA) pipeline across Phase 3, Phase 2. Its lead program is Vancomycin inhalation powder (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Savara Inc's next FDA catalyst?→
Savara Inc's (SVRA) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SVRA biotech catalysts?→
Add SVRA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Savara Inc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.